血清抵抗素与外周动脉疾病患者内皮功能受损及更高不良心脏事件发生率相关
研究纳入106例外周动脉疾病(PAD)患者,于2011至2016年入组,检测血清抵抗素并行血流介导的血管舒张(FMD)评估,随访中位36个月。抵抗素四分位越高,FMD越低;校正后抵抗素每升高1 ng/mL,主要不良心脏事件(MACE)风险增加10%(HR 1.10,95%CI 1.00-1.20,P=0.04)。
要点
- 抵抗素四分位越高,FMD越低(I 9.1%±3.3% vs IV 5.6%±3.5%,P=0.002)。
- 校正后抵抗素每升高1 ng/mL,MACE风险增加10%(HR 1.10,95%CI 1.00-1.20,P=0.04)。
- 抵抗素可能是PAD患者血管生理受损及不良心脏结局的标志物或效应物。
核心结论
- 在PAD患者中,较高的抵抗素水平与内皮功能受损及更高的MACE发生率相关。
- 作者认为抵抗素可能是PAD患者血管生理受损和不良心脏结局的标志物或效应物。
- 作者指出需进一步研究以确定抵抗素损害内皮功能并增加MACE的潜在机制。
研究设计与样本
- 研究纳入2011至2016年间招募的106例PAD患者,进行基线血管生理评估并检测血清抵抗素。
- 以研究入组时间作为起点,通过后续病历回顾识别新发MACE,定义为心肌梗死、冠状动脉血运重建、短暂性脑缺血发作、卒中或心源性死亡的复合终点。
主要发现
- 患者平均年龄68±8岁,75%为白人,合并高血压92%、高脂血症87%、冠心病37%、糖尿病38%。
- 按抵抗素四分位分层,较高四分位与年龄更大、吸烟包年数更多及估算肾小球滤过率更低显著相关。
- FMD随抵抗素四分位升高而显著降低(I 9.1%±3.3%;II 7.1%±3.5%;III 5.8%±4.0%;IV 5.6%±3.5%;P=0.002)。
- 多变量线性回归校正患者特征、药物及合并症后,抵抗素四分位III和IV相对四分位I与更低FMD相关(III -2.26,95%CI -4.51至-0.01,P=0.05;IV -2.53,95%CI -4.87至-0.20,P=0.03)。
- 中位随访36个月(四分位距29-45个月)期间,21例患者发生主要终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究以确定抵抗素损害内皮功能并增加MACE的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Resistin is a hormone that has been associated with metabolic syndrome and cardiovascular disease. The role of resistin in patients with peripheral artery disease (PAD) has not been fully explored. This study seeks to understand the relationship between serum resistin, vascular function, and cardiovascular outcomes in patients with PAD. METHODS: There were 106 patients with PAD who were recruited between 2011 and 2016. Patients attended a baseline visit during which a comprehensive vascular physiology assessment including medical and surgical history, radial artery tonometry, and flow mediated-vasodilation (FMD) was completed. A blood sample was drawn, and serum resistin was assayed using enzyme-linked immunosorbent assay kits. Using the time of study enrollment as the time of origin, incident major adverse cardiac events (MACEs) were identified by subsequent chart review and defined as a composite end point of myocardial infarction, coronary revascularization, transient ischemic attack, stroke, or death from a cardiac cause. RESULTS: Patients had a mean age of 68 ± 8 years, were largely white (75%), and had comorbidities commonly associated with PAD including hypertension (92%), hyperlipidemia (87%), coronary artery disease (37%), and diabetes mellitus (38%). After stratification by resistin quartile, higher resistin quartiles were significantly associated with an older age, a greater number of pack-years smoked, and a lower estimated glomerular filtration rate. Despite similar comorbidities and medication use, endothelial function, as measured by FMD, was significantly lower with increasing resistin quartile (I, 9.1% ± 3.3%; II, 7.1% ± 3.5%; III, 5.8% ± 4.0%; IV, 5.6% ± 3.5%; P = .002). In multivariable linear regression, higher resistin quartiles (III and IV) were associated with lower FMD relative to quartile I after adjusting for several patient characteristics, medications, and comorbidities (III, -2.26 [95% confidence interval (CI), -4.51 to -0.01; P = .05]; IV, -2.53 [95% CI, -4.87 to -0.20; P = .03]). During a median follow-up period of 36 months (interquartile range, 29-45 months), 21 patients experienced the primary end point. In a Cox proportional hazards model adjusted for smoking status, coronary artery disease, and age, each 1 ng/mL increase in resistin was associated with a 10% increased risk of MACEs (hazard ratio, 1.10; 95% CI, 1.00-1.20; P = .04). CONCLUSIONS: In patients with PAD, higher levels of resistin were associated with impaired endothelial function and an increased rate of MACEs. These results suggest that resistin may be a marker or effector of impaired vascular physiology and adverse cardiac outcomes in patients with PAD. Further research is needed to determine the potential mechanisms by which resistin may impair endothelial function and increase MACEs in this population.
引用
- Ramirez JL, Khetani SA, Zahner GJ, et al. Serum resistin is associated with impaired endothelial function and a higher rate of adverse cardiac events in patients with peripheral artery disease. J Vasc Surg. 2018. PMID: 30292618. doi:10.1016/j.jvs.2018.05.251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。